China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.7
38.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio pharmaceutical Group Co Ltd
Additional Paid In Capital
China Resources Boya Bio pharmaceutical Group Co Ltd
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
|
Additional Paid In Capital
¥4.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
16%
|
CAGR 10-Years
24%
|
|
|
Beigene Ltd
HKEX:6160
|
Additional Paid In Capital
¥81.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Additional Paid In Capital
¥4.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Additional Paid In Capital
¥3.3B
|
CAGR 3-Years
95%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Additional Paid In Capital
¥13.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
35%
|
CAGR 10-Years
20%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
China Resources Boya Bio pharmaceutical Group Co Ltd
Glance View
Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi and currently employs 1,652 full-time employees. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.
See Also
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
4.1B
CNY
Based on the financial report for Sep 30, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Additional Paid In Capital amounts to 4.1B CNY.
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
24%
Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been 28% over the past three years , 16% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet
